Kiniksa Pharmaceuticals Files 8-K on Shareholder Vote Matters

Ticker: KNSA · Form: 8-K · Filed: 2024-06-05T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

TL;DR

Kiniksa held a shareholder vote. Details TBD.

AI Summary

Kiniksa Pharmaceuticals, Ltd. filed an 8-K on June 5, 2024, to report on the submission of matters to a vote of security holders. The filing does not contain specific details about the vote itself, such as proposals or outcomes, but confirms the event occurred on or before June 5, 2024.

Why It Matters

This filing indicates that Kiniksa Pharmaceuticals held a shareholder vote, a standard corporate governance event that can signal important decisions or changes within the company.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any new financial information or significant corporate events that would immediately impact risk.

Key Players & Entities

FAQ

What specific matters were submitted for a vote of security holders?

The filing does not specify the exact proposals or matters that were submitted for a vote of security holders.

When was the shareholder meeting or vote held?

The filing states the date of the earliest event reported is June 5, 2024, indicating the vote occurred on or before this date.

What was the outcome of the shareholder vote?

The filing does not disclose the results or outcome of the shareholder vote.

Are there any details about the number of shares voted or the percentage of approval for any proposals?

No, the filing does not provide any information regarding the number of shares voted or the approval percentages.

Does this filing relate to any specific corporate actions like mergers or executive compensation changes?

The filing only states that it is a 'Submission of Matters to a Vote of Security Holders' and does not provide further context on the nature of these matters.

Filing Stats: 1,180 words · 5 min read · ~4 pages · Grade level 11.7 · Accepted 2024-06-05 16:27:43

Key Financial Figures

Filing Documents

07 Submission of Matters to a Vote of Security

Item 5.07 Submission of Matters to a Vote of Security Holders. A. Annual Meeting of Shareholders On June 5, 2024, Kiniksa Pharmaceuticals, Ltd. (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting") at which a quorum was present. Holders of the Company's Class A common shares ("Class A Shares") and Class B common shares ("Class B Shares") as of the close of business on April 15, 2024 (the "Record Date") were entitled to notice of and to vote at the Annual Meeting. Each Class A Share was entitled to one vote per share and each Class B Share was entitled to ten votes per share. The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 23, 2024 (the "Proxy Statement"). Proposal 1 – The election of Felix J. Baker, Ph.D., Tracey L. McCain and Kimberly J. Popovits as Class III Directors to serve until the 2027 Annual Meeting of Shareholders and until their respective successors have been duly elected and qualified. Nominee Votes FOR Votes WITHHELD Broker Non - Votes Felix J. Baker, Ph.D. 31,885,339 15,812,807 3,067,059 Tracey L. McCain 46,746,052 952,094 3,067,059 Kimberly J. Popovits 46,745,428 952,718 3,067,059 Proposal 2 – The (a) appointment of PricewaterhouseCoopers LLP as the Company's auditor until the close of the Company's next Annual Meeting of Shareholders, (b) delegation to the Company's Board of Directors, through the Audit Committee of the Board of Directors, of the authority to set the auditor's remuneration for such period, and (c) ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non - Votes 50,512,245 217,508 35,452 0 Proposal 3 – The ap

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINIKSA PHARMACEUTICALS, LTD. Date: June 5, 2024 By: /s/ Madelyn Zeylikman Madelyn Zeylikman Senior Vice President, General Counsel and Secretary

View on Read The Filing